SurModics (SRDX) Tops Q1 EPS by 13c, Revenues Beat; Offers FY20 EPS Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Surmodics Reports First Quarter Fiscal 2020 Results
February 5, 2020 4:05 PM ESTEDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 first quarter ended December 31, 2019.
Summary of First Quarter and Recent Highlights
Revenue of $22.6 million, an increase of 2% year-over-year GAAP EPS of $0.01, non-GAAP EPS of $0.05 Partnership announced with Medtronic for distribution of TelemarkTM coronary support catheterDuring the first quarter, we made important progress on our major strategic objectives while delivering an eighth consecutive... More
